Lupin Limited announced that Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada.
Rymti® is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
“Lupin is committed to enhancing patient access to high-quality, life-enhancing biosimilars,” said Dr. Cyrus Karkaria, President, Lupin Biotech. “The approval for Rymti® in Canada is a key milestone in our endeavors to improving access to medicines. It underscores the scientific success of Lupin’s biosimilar programs and our commitment to advancing healthcare through innovation.”
“The approval of Rymti® is an important first step for Lupin’s biosimilar franchise in Canada,” said Dr. Sofia Mumtaz, President – Legal & Compliance and Canada, Australia, and Japan. “We believe biosimilars will provide more Canadians with access to quality treatment, while reducing healthcare costs.”
